Activation Immunotherapy
Accumulating case reports now support the observation that a number of complex, chronic conditions can be improved by restoring VDR function using Inflammation Therapy. [1-3] In the absence of evidence based on clinical trials, the determination of when to use off-label olmesartan and an antibiotics protocol should be made on the basis of the doctor's best judgment (using diagnosis, severity of symptoms, history, potential disease course, previous treatments attempted, efficacy of traditional treatments and risk versus potential benefit, etc.) plus consideration of the patient's values.
This type of treatment requires several years (to avoid intolerable JHR) and patients must be highly motivated, but dramatic improvement has been seen (e.g., reduction in inflammatory symptoms, decrease in viral and antibody titers, normalization of lab work, improvement in bone density and correction of hormonal imbalances, etc.) in a wide variety of chronic inflammatory and autoimmune diseases. [4-6] It is becoming increasingly clear that microbes slow down immune reactivity by dysregulating the VDR, ultimately to increase their chance of survival. Immune modulatory therapies that enhance VDR expression and activity should, therefore, be considered in the clinical setting. [7]
References
1. Waterhouse JC, Perez TH, Albert PJ. Reversing bacteria-induced vitamin D receptor dysfunction is key to autoimmune disease. Ann NY Acad Sci. 2009;1173:757-765.
2. Proal AD, Albert PJ, Marshall TG. The human microbiome and autoimmunity. Curr Opin Rheumatol. Mar 2013;25(2):234-40.
3. Proal AD, Albert PJ, Blaney GP, Lindseth IA, Benediktsson C, Marshall TG. Immunostimulation in the era of the metagenome. Cell Mol Immunol. May 2011(8(3)):213-25.
4. Proal AD, Albert PJ, Marshall TG, Blaney GP, Lindseth LA. Immunostimulation in the treatment for chronic fatigue syndrome/myalgic encephalomyelitis. Immunol Res. Apr 2013;[published online ahead of print April 11, 2013].
5. Mangin M. Monitoring cognitively-disabled subjects in an interactive Internet-based clinical trial of a multi-factorial treatment based on a molecular model of chronic disease. Paper presented at: Days of Molecular Medicine Conference, Karolinska Institut, 2008; Stockholm, Sweden.
6. Mangin M. Monitoring recovery from autoimmune disease with an interactive, internet-based clinical trial based on a molecular model of chronic disease. Paper presented at: 6th International Congress on Autoimmunity, 2008; Porto, Portugal.
7. Kongsbak M, Levring TB, Geisler C, von Essen MR. The vitamin D receptor and T cell function. Front Immunol. Jun 2013;4:148.
Gradual reduction in symptoms during
Inflammation Therapy
|